View Older Stories View More Recent Stories
-
Keryx Biopharma (KERX) Well-Positioned for Zerenex Approval in 2014 - Roth Capital
-
Rexahn Pharma (RNN) Announces $20M Registered Direct Offering
-
Regeneron (REGN) Remains Strong Buy Following Recent Positive News - Roth Capital
-
Roth Capital Raises PT on Galena Biopharma (GALE) Following Deal with Dr. Reddy's (RDY)
-
Concert Pharmaceuticals (CNCE) Files $74.75M IPO
-
Notable 52-Week Highs and Lows of the Day 01/13: (RNN) (NVAX) (SWKS) High; (LULU) (SODA) Low
-
Roth Capital Keeps ImmunoCellular (IMUC) at Neutral; Sidelined Until More ICT-107 Answers Appear
-
Applied Genetic Technologies (AGTC) Files $70M IPO
-
Notable Mergers and Acquisitions of the Day 01/13: (BEAM) (GG) (GALE) (FWLT) (VC)/(JCI)
-
Roth Capital Raises PT on Galena Biopharma (GALE) Following Mills Pharmaceuticals Purchase
-
Galena Biopharma (GALE) Acquires GALE-401 Rights Owner, Mills Pharmaceuticals
-
Galena Biopharma Acquires Mills Pharmaceuticals, LLC
-
Retrophin (RTRX) Prices 4.7M Common Offering at $8.50/Share
-
Roth Capital Sees Synta Pharma (SNTA) Ganetespib Trial Updates as Positive; Affirms 'Buy' Rating
-
Notable 52-Week Highs and Lows of the Day 01/09: (RNN) (M) (WAG) High; (MRGE) (LULU) Low
-
Roth Capital Keeps Sunesis Pharma (SNSS) at Buy; Hematology Expansion Positive, Eyes Still on VALOR
-
Roth Capital Starts Rexahn Pharma (RNN) at Buy; Pieces in Place for Ground-Floor Opportunity
-
Notable Analyst Rating Changes 01/09: (JCP) (M) (AET) Upgraded; (BWLD) (S) (NVDA) Downgraded
-
Pre-Open Stock Movers 1/9: (ICPT) (CRDC) (F) Higher; (YRCW) (FDO) (PIR) Lower (more...)
-
Roth Capital Starts Rexahn Pharmaceuticals Inc. (RNN) at Buy
-
PlacementTracker Publishes 2013 PIPE Market League Tables
-
Roth Capital Starts ANI Pharmaceuticals (ANIP) at Buy
-
Notable Analyst Rating Changes 01/03: (SIRI) (FNSR) (PPL) Upgraded; (EXC) (MU) (S) Downgraded
-
Pre-Open Stock Movers 1/3: (FEYE) (GV) (FNSR) Higher; (RFIL) (JMBA) (S) Lower (more...)
-
Roth Capital Starts FX Energy (FXEN) at Buy
-
Pre-Open Stock Movers 12/23: (DRCO) (XRTX) (APPL) Higher; (TSRO) (MU) (TIF) Lower (more...)
-
Can-Fite BioPharma (CANF) Target Raised to $28 at Roth Capital
-
UPDATE: Roth Capital Upgrades Skullcandy (SKUL) to Buy
-
Ur-Energy (URG) Closes Pathfinder Mines Corp Acquisition
-
Roth Capital resumed Digital Generation (DGIT) at Buy
-
Roth Capital Starts Synergy Resources Corporation (SYRG) at Buy
-
GigOptix (GIG) Prices 8.33M Offering at $1.42/Share
-
Roth Capital Starts Diamondback Energy (FANG) at Buy
-
Spectrum Pharma (SPPI) Prices $100M 2.75% Covertible Notes Offering
-
Roth Capital Starts Sequential Brands (SQBG) at Buy
-
Roth Capital Starts Sapiens International Corp. NV (SPNS) at Buy
-
Kindred Biosciences (KIN) IPO Opens Sharply Higher
-
Kindred Biosciences (KIN) IPO Prices at $7, Middle of Range
-
Roth Capital Downgrades ImmunoCellular Therapeutics (IMUC) to Neutral
-
Roth Capital Upgrades Hudson Technologies (HDSN) to Buy
-
Ring Energy (REI) Prices 5M Common Stock Offering at $10/Share
-
Roth Capital Starts Attunity (ATTU) at Buy
-
Roth Capital Starts Tangoe (TNGO) at Buy
-
Intellipharmaceutics (IPCI) Announces 5.3M 'At-The-Market' Offering
-
Notable 52-Week Highs and Lows of the Day 11/26: (IMUC) (YPF) (TIF) High; (NUAN) (EBAY) Low
-
Unusual 11 Mid-Day Movers 11/26: (MBIS) (ECTE) (ELTK) Higher; (ZX) (NUAN) (SSN) Lower
-
Cedars-Sinai Brain Cancer Study Shows 50% vs 10% of Patients Alive After Five Years (IMUC)
-
Unusual 11 Mid-Day Movers 11/25: (CAMT) (PBMD) (ARIA) Higher; (ICLD) (UNXL) (RCON) Lower
-
ImmunoCellular (IMUC) Continues Higher After Added to Focus List at Roth
-
Roth Capital Starts GigOptix (GIG) at Buy

